RT Journal Article
T1 Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen.
A1 Ruiz-Sánchez, Daniel
A1 Alaguero Calero, Miguel
A1 Sastre-Heres, Alejandro José
A1 Iglesias García, María Teresa
A1 Calleja Hernandez, Miguel Angel
A1 Martínez Martinez, Fernando
A1 Peña-Díaz, Jaime
K1 Bevacizumab
K1 Irinotecan
K1 Effectiveness
K1 Antineoplásicos
K1 Camptotecina
K1 Análisis de Supervivencia
K1 Estudios de Cohortes
K1 Anticuerpos Monoclonales
K1 Resultado del Tratamiento
AB A retrospective cohort study was conducted to analyse the effectiveness of bevacizumab and irinotecan (BVZ/CPT-11) as a second-line treatment in patients with primary glioblastoma multiforme (GBM) in comparison with a control group that were not administered BVZ/CPT-11 at the first recurrence. The difference in overall survival (OS) between the two groups was used as a predictor of effectiveness. OS was calculated according to prognostic factors and gender. A total of 28 and 32 patients were enrolled in the BVZ/CPT-11 cohort and control group, respectively. The median OS was 17.94 months (95% CI, 14.91-20.96) in the BVZ/CPT-11 treatment cohort and 10.97 months (95% CI, 7.65-14.30) in the control cohort. The results obtained on the effectiveness of BVZ/CPT-11 treatment in patients with primary GBM are consistent with data from previous studies. No significant differences were identified in OS based on prognostic factors; therefore, the latter cannot be used to select patients who would incur the greatest benefits from BVZ/CPT-11 treatment.
PB Spandidos Publications
YR 2012
FD 2012-11
LK http://hdl.handle.net/10668/1406
UL http://hdl.handle.net/10668/1406
LA en
NO Ruiz-Sánchez D, Alaguero Calero M, Sastre-Heres AJ, Iglesias García MT, Calleja Hernández MA, Martínez Martínez F, et al. Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen. Oncol Lett. 2012; 4(5):1114-1118.
NO JOURNAL ARTICLE;
DS RISalud
RD Apr 8, 2025